Diversified Trust Co Acquires 16,792 Shares of Becton, Dickinson and Company $BDX

Key Points

• Diversified Trust Co sharply increased its Becton, Dickinson stake in Q1, buying 16,792 additional shares and lifting its total holdings to 18,002 shares worth about $2.83 million.
• Institutional ownership remains heavy, with hedge funds and other large investors owning 86.97% of BDX. Several major firms, including Vanguard and State Street, also reported changes to their positions.
• BDX reported solid quarterly results, beating EPS and revenue estimates with $2.90 per share on $4.71 billion in revenue, while also raising fiscal 2026 guidance to $12.52-$12.72 EPS. The company pays a quarterly dividend of $1.05 per share, yielding about 2.9%.

Diversified Trust Co boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1,387.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,002 shares of the medical instruments supplier's stock after purchasing an additional 16,792 shares during the period. Diversified Trust Co's holdings in Becton, Dickinson and Company were worth $2,830,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BDX. Auto Owners Insurance Co boosted its holdings in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after acquiring an additional 40,528,680 shares during the period. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. State Street Corp lifted its position in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock valued at $2,714,871,000 after purchasing an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Becton, Dickinson and Company by 3.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock worth $1,841,083,000 after purchasing an additional 336,110 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Argus lowered their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a report on Monday, March 23rd. Zacks Research upgraded shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. TD Cowen dropped their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a report on Monday, May 4th. Finally, Evercore boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $181.00.

Becton, Dickinson and Company Trading Up 0.0%

Shares of BDX opened at $143.99 on Monday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm's 50-day moving average price is $148.89 and its 200-day moving average price is $172.17. The firm has a market capitalization of $39.67 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 10.19 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 EPS. The business's revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company's stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,013 shares of company stock worth $593,434. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.